On July 23, Danaher rose 3.16% in pre-market trading, trading at approximately $184.00/share, with turnover of $4.27 million, staging a recovery after cumulative declines of roughly 20% over the prior two sessions.

The rebound comes as the market digests institutional support despite recent target price cuts. Morgan Stanley lowered its target from $255 to $220 while maintaining an Overweight rating, and Evercore ISI reduced its target from $230 to $205. The current consensus mean price target of $227.50 remains significantly above the current trading level, providing valuation support for an oversold bounce.

The prior sell-off was triggered by the company's Q2 earnings release on July 21, where despite beating estimates with adjusted EPS of $1.94 versus the $1.83 consensus and revenue of $6.265 billion versus $6.102 billion expected, Danaher guided Q3 non-GAAP core revenue growth of only 2.0%-3.0%, well below Q2 performance. Concerns over the growth deceleration and integration risks from recent acquisitions including the approximately $10 billion Masimo deal compounded selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)